Tohoku Univ. Technology：A Diagnostic Test Enabling Precision Oncology in Head and Neck Cancer：T25-030
Predicts Therapeutic Response to ICI and Anti-EGFR Antibody Treatments
For patients with platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), first-line therapy usually involves pembrolizumab (an immune checkpoint inhibitor; ICI) with chemotherapy (5-FU plus cisplatin/carboplatin), or pembrolizumab alone for PD-L1–positive cases defined by the combined positive score (CPS). As a second-line option, cetuximab (anti-EGFR antibody) plus paclitaxel (CET+PTX) is commonly used. Our study revealed a mutually exclusive correlation between responses to first-line pembrolizumab and second-line CET+PTX. Comprehensive gene expression analyses identified key biomarkers linked to this correlation. This diagnostic approach allows prediction of each therapy’s efficacy in individual patients by measuring these biomarkers.
Inquire About This Product
basic information
please contact us or refer to the PDF for more details.
Price range
Delivery Time
Applications/Examples of results
please contact us or refer to the PDF for more details.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested as new research funding for universities and researchers, and is utilized to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will vigorously promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by signing basic technology transfer agreements with the following universities (as of June 1, 2025): Tohoku University, Hirosaki University, Iwate University, Akita University, Fukushima University, Yamagata University, Tohoku Gakuin University, Iwate Medical University, Fukushima Medical University, Aizu University, Miyagi University, Hokkaido University, Muroran Institute of Technology, and Showa Medical University.
![[Market Report] Global Market for Point-of-Care Diagnostic Tests](https://image.mono.ipros.com/public/product/image/123/2000940437/IPROS17678327490617014341.jpeg?w=280&h=280)
![[Research Material] Global Market for Bladder Cancer Treatment Drugs](https://image.mono.ipros.com/public/product/image/3aa/2001460626/IPROS40391824380644179480.jpeg?w=280&h=280)
![[Research Material] The Global Market for Oral Antidiabetic Drugs (OAD) Treatment](https://image.mono.ipros.com/public/product/image/122/2001481185/IPROS09893343157688030762.jpeg?w=280&h=280)
![[Heat Shield Product Comparison] Rooftop Natural Energy Applied Heat Shield Sheet 'Cool Roof'](https://image.mono.ipros.com/public/product/image/6b6/2000628115/IPROS79846363654755276596.png?w=280&h=280)
